Cullinan Oncology to Present New Preclinical Data for
CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial...
Source: globenewswire.com
Page 4 - Nasdaq Cgem News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq Cgem. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Cgem Today - Breaking & Trending Today
Cullinan Oncology Licenses U.S. Rights to the First
CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan...
Source: globenewswire.com
Cullinan Oncology Reports Inducement Grants Under Nasdaq
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on...
Source: globenewswire.com
Cullinan Oncology Reports Inducement Grants Under Nasdaq
CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on...
Source: globenewswire.com
Cullinan Oncology Reports Inducement Grants Under Nasdaq
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on...
Source: globenewswire.com